This phase I trial is evaluating an intratumoural injection in patients with skin cancer and cancers of the head and neck.
This trial is treating multiple types of cancer including skin cancer or cancers of the head and neck.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
- You have a certain disease or psychological condition.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46 in Patients with Refractory Cutaneous or Subcutaneous Tumours
This study aims to evaluate the safety and tolerability of a new investigational drug called EBC-46 in participants with advanced cancer. Who is it for?
Patients may be eligible to join this study if aged 18 years or more and have been diagnosed with an advanced cutaneous or subcutaneous tumour.
All participants in this study will receive a single EBC-46 injection directly into tumours. EBC-46 may lead to breakdown of tumour blood vessels and recruitment and activation of white blood cells. This leads to rapid tumour cell death. This drug has not previously been tested in humans. Participants will be monitored for 3 weeks following EBC-46 injection in order to evaluate safety, tolerability, tumour response and pharmacokinetics (the action of the body on the drug).
The results from this study will be analysed to see if it is worthwhile for this new drug to be tested in future studies involving larger numbers of cancer participants.